SCT-001 CAR-T cell therapy is positioned to address a significant unmet need in the treatment of recurrent and refractory epithelial ovarian, fallopian tube, and peritoneal cancers, which are often resistant to standard therapies. The open-label, dose-escalation design allows for the evaluation of safety and preliminary efficacy, which could provide a competitive edge in the CAR-T landscape, particularly in solid tumors. The dual administration routes (intraperitoneal and intravenous) may enhance patient accessibility and treatment personalization. The market for ovarian cancer therapies is growing, with increasing investment in immunotherapies, suggesting potential for substantial commercial success if efficacy is demonstrated. However, the competitive landscape includes established players in CAR-T and emerging therapies targeting similar indications, necessitating a robust clinical outcome to differentiate SCT-001.